Genes shape GLP‑1 response
Researchers say genetic variants may explain why about 10% of people respond poorly to GLP‑1 weight‑loss drugs such as Ozempic and Wegovy. ScienceDaily reported roughly 10% show signs of 'GLP‑1 resistance,' and Medscape noted two specific genetic variants linked to differences in both efficacy and side effects for GLP‑1 therapies like Mounjaro ( ).
Glucagon-like peptide 1 drugs mimic a gut hormone that helps control blood sugar and appetite, and two new studies say genes help explain why some people respond differently. (med.stanford.edu; nature.com) In one study published April 10 in *Genome Medicine*, Stanford Medicine and collaborators reported that genetic variants carried by about 10% of the population were linked to weaker blood-sugar responses to glucagon-like peptide 1 receptor agonists, a pattern the researchers called “glucagon-like peptide 1 resistance.” (med.stanford.edu; sciencedaily.com) That Stanford team said more than a quarter of people with Type 2 diabetes take these drugs, but some variant carriers lowered blood glucose less effectively after six months of treatment in trial data reviewed over a decade-long international project. (med.stanford.edu) A second study, published April 8 in *Nature*, looked at 27,885 people using glucagon-like peptide 1 medicines and found a missense variant in the GLP1R gene tied to greater weight-loss efficacy, with an additional 0.76 kilograms of weight loss per copy of the effect allele. (nature.com) That same *Nature* study also linked variation in GLP1R and GIPR, another gut-hormone receptor gene, to nausea or vomiting, and found the GIPR side-effect signal only among people using tirzepatide rather than semaglutide. (nature.com) The distinction matters because semaglutide is sold as Ozempic for diabetes and Wegovy for obesity, while tirzepatide is sold as Mounjaro for diabetes and Zepbound for obesity; both drug families are now used widely enough that even a minority of poor responders adds up to large numbers of patients. (nature.com; med.stanford.edu) The two papers do not answer the same question. The Stanford work focused on blood-sugar control in diabetes and said it is still unclear whether its resistance-linked variants also change weight-loss outcomes from drugs such as Ozempic and Wegovy. (med.stanford.edu; sciencedaily.com) The 23andMe-led *Nature* paper focused on obesity treatment response and side effects, using self-reported outcomes to build a model that the authors said could sort patients by likely benefit and risk. (nature.com) Researchers in both reports pointed toward precision medicine, meaning treatment matched to a patient’s biology rather than trial and error after months on a drug. Stanford’s Anna Gloyn said knowing likely response in advance could help patients get on the right drugs faster. (med.stanford.edu) For now, the message from the new data is narrower than the hype around these medicines: genes appear to shape who loses more weight, who gets more nausea, and who may see less blood-sugar benefit, but doctors still do not have a standard genetic test to guide prescribing. (nature.com; med.stanford.edu)
